✓ Reviewed by Dr. Sharma, MD · Updated 2026-05-10

Why We Choose to Compound — and the Clinical Rationale Behind It

Name: Why We Choose to Compound — Our Clinical Rationale
Published: 2026-05-10

"Why don't you just dispense Wegovy?" gets asked at almost every consult. Here's the honest answer: there are five clinical reasons, plus an economic one. We'll walk through each.

The short version. Compounded semaglutide and tirzepatide let us titrate doses with a precision that the brand-name pre-filled pens can't, layer in B12 or lipotropic support, control the supplier and request a Certificate of Analysis, and offer the program at a price most patients can sustain across a 6–12 month protocol. None of those reasons depend on cost being the driver — and we'll still recommend brand-name when it's the right call.

1. Individualized dose titration

Brand-name semaglutide pens come in fixed step doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg for Wegovy; similar steps for Ozempic). For most patients, the steps work fine. For some, the jumps are too big — gastrointestinal side effects spike at the next step, the patient drops out, weight regain follows.

A compounded preparation in a vial lets us prescribe exactly the dose the patient tolerates. Half-step titrations, holding doses, custom maintenance protocols at fractional doses — all are easier when the medication is dispensed in milligrams, not pen clicks.

2. B12 and lipotropic add-ons

GLP-1 therapy reduces appetite, which can subtly reduce intake of foods that supply vitamin B12, methionine, and other nutrients important to energy and metabolic function. We frequently combine semaglutide or tirzepatide with B12 (cyanocobalamin or methylcobalamin) and lipotropic compounds (methionine, inositol, choline). These add-ons aren't available in the brand-name pen because the pen is a single-active-ingredient product.

The combination is what most patients describe as "I have actual energy on this protocol, not just less hunger."

3. Supplier control and Certificate of Analysis

We work only with state-licensed 503(a) sterile compounding pharmacies. The active pharmaceutical ingredient is sourced from FDA-registered facilities. Every batch is potency-tested and sterility-tested.

If a patient asks for the Certificate of Analysis for the lot they received, we provide it. The brand-name supply chain is also traceable — but the COA isn't something the average retail pharmacy will hand over for a Wegovy pen. Compounding gives us tighter control of who's making the medication and what's in it.

Avoid these compounders. Sketchy "research peptide" vendors, offshore peptide marketplaces, anyone selling "not for human use" labeled products — all of these are dangerous and not what 503(a) compounding refers to. Always verify your physician sources from a state-licensed U.S. compounding pharmacy, and ask for a COA.

4. Continuity through supply disruptions

2022–2024 saw repeated FDA-declared shortages of brand-name semaglutide and tirzepatide. Patients on brand-name products experienced gaps in therapy — some lost months of progress. Compounded preparations from 503(a) pharmacies remained more consistently available during those windows.

The brand-name supply has stabilized as of 2025–2026. If shortages return, having a compounded protocol option means continuity.

5. Total-cost transparency

Brand-name therapy without insurance is roughly $1,069 to $1,349 per month, plus the office visits to prescribe and adjust dose, plus any labs. Across a 12-month protocol that adds up substantially.

NHWL's compounded program is bundled: $499 (semaglutide) or $699 (tirzepatide) for 90 days, including the physician oversight, dose adjustments, and basic labs. There are no separate visit fees during the program. For a patient committing to a 6–12 month transformation, the total-cost difference is what makes the program sustainable.

6. The economic reality (we won't pretend otherwise)

For uninsured patients, $1,349/month is not a sustainable monthly expense for most households. Compounded therapy at $166/month makes the protocol accessible. This isn't the only reason we compound — but it's the reason most patients find their way to us.

If your insurance covers brand-name and your out-of-pocket is comparable, brand-name is usually the better path. We tell patients this directly during the consultation. We're not in the business of talking patients into compounded when brand-name fits their situation.

What we won't do

We won't claim equivalence to brand-name. "The same as Ozempic" isn't a phrase we use — it's the FDA's definition of what 503(a) pharmacies can't compound, and saying it would be both legally and clinically careless.
We won't dispense without a doctor's review. Every prescription requires Dr. Sharma's evaluation of the patient's medical history. No exceptions.
We won't compound for patients with contra-indications. History of medullary thyroid carcinoma, MEN-2 syndrome, active pancreatitis, severe gastroparesis, current pregnancy or breastfeeding — these all rule out GLP-1 therapy at our clinic.
We won't sell sterility or safety claims we can't back up. We provide the COA on request. We tell patients which pharmacy filled their prescription. If you ask, we put it on the invoice.

What this means for you

If compounded therapy is a fit for your situation — uninsured or underinsured for GLP-1, want individualized titration, want bundled physician oversight at a sustainable monthly cost — we're a strong option. If brand-name fits better, we'll tell you that and refer you. The qualifying quiz starts the conversation.

This page is informational only and not medical advice. Speak with a licensed physician before starting any GLP-1 therapy. Individual results vary. New Hope Weight Loss dispenses compounded semaglutide and compounded tirzepatide via state-licensed 503(a) pharmacies. We do not dispense Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded medications are not FDA-approved products. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by these companies.